Leerink Partnrs Comments on United Therapeutics Co.’s Q3 2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Analysts at Leerink Partnrs lifted their Q3 2024 EPS estimates for United Therapeutics in a note issued to investors on Tuesday, March 26th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $6.90 per share for the quarter, up from their prior estimate of $6.31. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2024 earnings at $6.94 EPS, FY2025 earnings at $27.09 EPS, FY2026 earnings at $27.29 EPS and FY2027 earnings at $26.52 EPS.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same period last year, the firm posted $2.67 earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year.

UTHR has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Wedbush reissued an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company raised their target price on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $294.40.

United Therapeutics Trading Down 5.6 %

Shares of UTHR stock opened at $229.72 on Friday. The firm has a 50-day moving average price of $225.77 and a 200 day moving average price of $227.41. United Therapeutics has a twelve month low of $204.44 and a twelve month high of $261.54. The company has a market capitalization of $10.81 billion, a price-to-earnings ratio of 11.58 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. GAMMA Investing LLC bought a new stake in United Therapeutics in the 4th quarter valued at about $43,000. Neo Ivy Capital Management purchased a new position in United Therapeutics in the second quarter valued at approximately $48,000. Atlas Capital Advisors LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth $51,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 49.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 65 shares in the last quarter. Finally, Zions Bancorporation N.A. purchased a new stake in shares of United Therapeutics during the first quarter worth $66,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $32,282.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $32,282.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $236.45, for a total value of $1,418,700.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $8,680,079.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,680 shares of company stock valued at $17,886,630. Company insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.